Shopping Cart 0
Cart Subtotal
USD 0

Vivus Inc (VVUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's marketed products include, Qsymia (phentermine and topiramate extended-release), indicated for the chronic weight management in adult patients; and Stendra/Spedra (avanafil), an oral phosphodiesterase type 5, for erectile dysfunction. Its pipeline products include Qsymia for obstructive sleep apnea, nonalcoholic steatohepatitis, diabetes, nonalcoholic fatty liver disease and hyperlipidemia; and Tacrolimus for pulmonary arterial hypertension. Vivus works in partnership with pharmaceutical companies to advance of its product portfolio. It operates through its subsidiaries in the UK, the Netherlands, Ireland and Bermuda. Vivus is headquartered in Campbell, California, the US.

Vivus Inc (VVUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vivus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Vivus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Vivus Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

VIVUS Acquires Assets from Janssen Pharma for USD135 Million 11

Vivus Acquires Topiramate Related Patents from Janssen Pharma 12

Venture Financing 13

Athyrium Opportunities Invests in Vivus 13

Partnerships 14

Vivus Plans To Enter Into Co-Marketing Agreement For Qsymia 14

Licensing Agreements 15

VIVUS Enters into Licensing Agreement with Selten Pharma 15

Hetero Enters into Licensing Agreement with VIVUS for STENDRA 16

Metuchen Pharma Enters into Licensing Agreement with Vivus 17

Vivus Enters Into Licensing Agreement With Menarini For Spedra 18

Equity Offering 20

Vivus Plans to Raise up to USD200 Million in Public Offering of Securities 20

VIVUS Completes Public Offering Of Common Stock For USD 202 Million 21

Debt Offering 23

Vivus to Raise Funds through public offering of 4.5% Convertible Bonds Due 2020 23

Vivus Completes Private Placement of Notes Due 2020 For USD 220 Million 24

Acquisition 25

Aspen Investment Plans to Acquire Remaining Interest in Vivus for USD640 Million 25

Vivus Inc-Key Competitors 26

Vivus Inc-Key Employees 27

Vivus Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Nov 01, 2018: VIVUS reports third quarter 2018 financial results 29

Aug 07, 2018: VIVUS reports second quarter 2018 financial results 31

May 08, 2018: VIVUS Reports First Quarter 2018 Financial Results 33

Mar 13, 2018: VIVUS Reports Fourth Quarter 2017 Financial Results 35

Nov 07, 2017: VIVUS Reports Third Quarter 2017 Financial Results 37

Aug 03, 2017: VIVUS Reports Second Quarter 2017 Financial Results 39

May 03, 2017: VIVUS Reports 2017 First Quarter Financial Results 41

Mar 08, 2017: VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results 42

Corporate Communications 44

Oct 29, 2018: VIVUS adds two new members to the Board of Directors 44

Sep 21, 2018: VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation's CF Climb 45

Aug 06, 2018: VIVUS names Kenneth Suh as president 47

Dec 26, 2017: VIVUS Announces Change in Leadership 48

May 24, 2017: Thomas B. King Joins VIVUS' Board of Directors 49

Product Approvals 50

Nov 02, 2017: VIVUS Completes Tacrolimus Pre-IND Meeting With FDA 50

Clinical Trials 51

Jul 10, 2018: VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Vivus Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vivus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vivus Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Vivus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

VIVUS Acquires Assets from Janssen Pharma for USD135 Million 11

Vivus Acquires Topiramate Related Patents from Janssen Pharma 12

Athyrium Opportunities Invests in Vivus 13

Vivus Plans To Enter Into Co-Marketing Agreement For Qsymia 14

VIVUS Enters into Licensing Agreement with Selten Pharma 15

Hetero Enters into Licensing Agreement with VIVUS for STENDRA 16

Metuchen Pharma Enters into Licensing Agreement with Vivus 17

Vivus Enters Into Licensing Agreement With Menarini For Spedra 18

Vivus Plans to Raise up to USD200 Million in Public Offering of Securities 20

VIVUS Completes Public Offering Of Common Stock For USD 202 Million 21

Vivus to Raise Funds through public offering of 4.5% Convertible Bonds Due 2020 23

Vivus Completes Private Placement of Notes Due 2020 For USD 220 Million 24

Aspen Investment Plans to Acquire Remaining Interest in Vivus for USD640 Million 25

Vivus Inc, Key Competitors 26

Vivus Inc, Key Employees 27

Vivus Inc, Subsidiaries 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Vivus Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's marketed products include, Qsymia (phentermine and topiramate extended-release), indicated for the chronic weight management in adult patients; and Stendra/Spedra (avanafil), an oral phosphodiesterase type 5, for erectile dysfunction. Its pipeline products include Qsymia for obstructive sleep apnea, nonalcoholic steatohepatitis, diabetes, nonalcoholic fatty liver disease and hyperlipidemia; and Tacrolimus for pulmonary arterial hypertension. Vivus works in partnership with pharmaceutical companies to advance of its product portfolio. It operates through its subsidiaries in the UK, the Netherlands, Ireland and Bermuda. Vivus is headquartered in Campbell, California, the US.

Vivus Inc (VVUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vivus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Vivus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Vivus Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

VIVUS Acquires Assets from Janssen Pharma for USD135 Million 11

Vivus Acquires Topiramate Related Patents from Janssen Pharma 12

Venture Financing 13

Athyrium Opportunities Invests in Vivus 13

Partnerships 14

Vivus Plans To Enter Into Co-Marketing Agreement For Qsymia 14

Licensing Agreements 15

VIVUS Enters into Licensing Agreement with Selten Pharma 15

Hetero Enters into Licensing Agreement with VIVUS for STENDRA 16

Metuchen Pharma Enters into Licensing Agreement with Vivus 17

Vivus Enters Into Licensing Agreement With Menarini For Spedra 18

Equity Offering 20

Vivus Plans to Raise up to USD200 Million in Public Offering of Securities 20

VIVUS Completes Public Offering Of Common Stock For USD 202 Million 21

Debt Offering 23

Vivus to Raise Funds through public offering of 4.5% Convertible Bonds Due 2020 23

Vivus Completes Private Placement of Notes Due 2020 For USD 220 Million 24

Acquisition 25

Aspen Investment Plans to Acquire Remaining Interest in Vivus for USD640 Million 25

Vivus Inc-Key Competitors 26

Vivus Inc-Key Employees 27

Vivus Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Nov 01, 2018: VIVUS reports third quarter 2018 financial results 29

Aug 07, 2018: VIVUS reports second quarter 2018 financial results 31

May 08, 2018: VIVUS Reports First Quarter 2018 Financial Results 33

Mar 13, 2018: VIVUS Reports Fourth Quarter 2017 Financial Results 35

Nov 07, 2017: VIVUS Reports Third Quarter 2017 Financial Results 37

Aug 03, 2017: VIVUS Reports Second Quarter 2017 Financial Results 39

May 03, 2017: VIVUS Reports 2017 First Quarter Financial Results 41

Mar 08, 2017: VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results 42

Corporate Communications 44

Oct 29, 2018: VIVUS adds two new members to the Board of Directors 44

Sep 21, 2018: VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation's CF Climb 45

Aug 06, 2018: VIVUS names Kenneth Suh as president 47

Dec 26, 2017: VIVUS Announces Change in Leadership 48

May 24, 2017: Thomas B. King Joins VIVUS' Board of Directors 49

Product Approvals 50

Nov 02, 2017: VIVUS Completes Tacrolimus Pre-IND Meeting With FDA 50

Clinical Trials 51

Jul 10, 2018: VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Vivus Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Vivus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Vivus Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Vivus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

VIVUS Acquires Assets from Janssen Pharma for USD135 Million 11

Vivus Acquires Topiramate Related Patents from Janssen Pharma 12

Athyrium Opportunities Invests in Vivus 13

Vivus Plans To Enter Into Co-Marketing Agreement For Qsymia 14

VIVUS Enters into Licensing Agreement with Selten Pharma 15

Hetero Enters into Licensing Agreement with VIVUS for STENDRA 16

Metuchen Pharma Enters into Licensing Agreement with Vivus 17

Vivus Enters Into Licensing Agreement With Menarini For Spedra 18

Vivus Plans to Raise up to USD200 Million in Public Offering of Securities 20

VIVUS Completes Public Offering Of Common Stock For USD 202 Million 21

Vivus to Raise Funds through public offering of 4.5% Convertible Bonds Due 2020 23

Vivus Completes Private Placement of Notes Due 2020 For USD 220 Million 24

Aspen Investment Plans to Acquire Remaining Interest in Vivus for USD640 Million 25

Vivus Inc, Key Competitors 26

Vivus Inc, Key Employees 27

Vivus Inc, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Vivus Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.